Reshape Lifesciences (NASDAQ:RSLS) will announce its earnings results after the market closes on Thursday, March 22nd.

Reshape Lifesciences (RSLS) opened at $1.43 on Thursday. Reshape Lifesciences has a 12 month low of $1.23 and a 12 month high of $7.30. The firm has a market cap of $42.84, a P/E ratio of -0.24 and a beta of 2.68.

How to Become a New Pot Stock Millionaire

A number of research analysts have weighed in on RSLS shares. Zacks Investment Research lowered shares of Reshape Lifesciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 6th. ValuEngine raised shares of Reshape Lifesciences from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at

About Reshape Lifesciences

ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Earnings History for Reshape Lifesciences (NASDAQ:RSLS)

Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with's FREE daily email newsletter.